Pencil-beam scanning proton re-irradiation showed low acute toxicity in recurrent head and neck cancer
Pencil-beam scanning proton re-irradiation achieved 17.2-month median survival with 7.7% grade 3 or higher oral mucositis.
Pencil-beam scanning proton re-irradiation achieved 17.2-month median survival with 7.7% grade 3 or higher oral mucositis.
SMART-BRAIN proton planning spared portions of non-target brain while maintaining target coverage in five medulloblastoma cases.
Dose-dependent linear energy transfer constraints aligned with published proton toxicity data better than fixed threshold approaches.
Upright computed tomography showed stable computed tomography numbers and greater than 99% proton dose gamma agreement versus conventional computed tomography.
Scanned and scattered clinical proton beams produced similar Ewing sarcoma cell survival despite higher oxidative stress signals after scanned delivery.
Aperture-enhanced proton stereotactic radiosurgery reduced normal brain dose compared with photon plans in most cerebral arteriovenous malformation cases.
Synthetic stopping power maps showed small target dose differences, but residual range and low-dose gamma errors still require further validation.
In ten paraspinal chordoma plans, direct cord robust optimization improved coverage and robustness while maintaining acceptable spinal cord doses.
In 180 thoracic proton therapy patients, larger clinical target volume and heart volume independently predicted the need for adaptive replanning.
Simulated proton minibeams preserved spatial fractionation and target homogeneity for targets up to 20 centimetres with depth-adapted beam widths and spacing.
Median survival was 8.3 months after proton reirradiation, with 5.6% grade 3–4 radiation necrosis and no survival difference versus photons.
Gastrointestinal motility reduced single-fraction target coverage and broadened organ-at-risk dose ranges, while conventional fractionation substantially attenuated the interplay effect.
Four-year overall survival was 81.2%, and starting proton therapy at week 14 or later was not independently associated with worse outcomes.
Respiratory gating more than halved cranio-caudal motion, while motion-related target-dose deviations largely diminished after accumulation across more than three fractions.
Hybrid phase-amplitude gating restored dose agreement during regular motion, while irregular breathing increased treatment time and produced inconsistent accuracy.